According to the latest report published by Acute Market Reports “Direct-to-Consumer (DTC) Genetic Testing Market - Growth, Future Prospects and Competitive Analysis, 2019-2029,” the global direct-to-consumer genetic testing market is expected to expand at a CAGR of 19.5% from 2021 to 2029.

Browse the full report Direct-to-Consumer (DTC) Genetic Testing Market - Growth, Future Prospects and Competitive Analysis, 2021-2029 report at https://www.acutemarketreports.com/report/direct-to-consumer-dtc-genetic-testing-market 

The Direct-to- consumer genetic testing market is forecast to grow CAGR to upto19.5% from 2021 to 2029. Over the past decade, technological advances have enabled to the companies to decode, and make sense of, the information contained in the genes at ever faster speeds and lower costs. Until relatively recently though, the principal application of this technology was in hospital-based diagnostic equipment. There are already over 250 companies offering customers DNA tests in applications including forensics, ancestry, health, pharmacogenomics, fitness and nutrition. Consumers are increasingly driven by self-curiosity and empowerment, reflected by an increase in awareness of services offering genetic testing and follow on advice. Direct-to-consumer testing is expanding the number of people who are able to get genetic testing of their DNA. Genome is made up of thousands of genes that carry the hereditary information about traits, such as eye colour or height. This information is based on the arrangement of distinct molecules that make up genes. Some of these arrangements, or variants, can be used to diagnose a rare disease, provide information about a person's risk of developing disease, or other types of information. Some variants have clinical significance and may give consumers insight into monitoring their own health, or about potential disease or conditions.

The FDA regulatory pathways for some types of DTC tests are described below. The agency is committed to working with all direct-to-consumer test companies to develop reasonable and efficient regulatory pathways for new types of clinically and analytically valid direct-to-consumer tests. Carrier Screening Tests, these tests can be used to determine whether a healthy person carries a genetic variant that could be passed on to their potential future children. Genetic Health Risk (GHR) Tests, GHR tests are intended to provide information on an individual's genetic risk for certain medical diseases or conditions. Pharmacogenetics tests provide information regarding the role genetics may play in an individual's reaction to drugs. The FDA has issued a safety communication to alert the public of concerns regarding pharmacogenetic tests with unapproved claims to predict an individual's response to a specific therapeutic drug where these claims may not supported by clinical evidence.

North America led the global DTC genetic testing market in 2020. Increasing awareness about the risk of genetic diseases and growing proactive tendency among the public about prevention and efficient management of chronic diseases mainly drive the North America market. Additionally, inquisitiveness about knowledge of lineage also prominently determine the significant sales in this region. Furthermore, Asia Pacific is estimated to be the fastest growing regional market during the forecast period. The growth of this region is mainly attributed to rapid evolution of healthcare infrastructure and increasing awareness about the availability of such tests kits. Key market players in the global DTC genetic testing market include deCODE genetics, Inc., Color Genomics, Inc., Gene By Gene, Ltd., Ancestry.com, Inc., Myriad Genetics, Inc., Genleven Oy, 23andMe, Inc., and CENTOGENE AG.

Key Market Movements:

• The Direct to consumer Geneticmarket is developing significantly with an expected CAGR of 19.5% from 2021 - 2029.
• Advances in technological processes are the key growth factor.
• Emerging technological advancement withrespect to laboratory testing has expanded the demand in Europe and North America.
• The key Circulation platforms are Online & in the centers.
• It has been observed that more people are willing to take this test.
• The impact of Covid-19 impacted the market and lowered the growth rate.
• North Amerca gained the largest share, followed by Europe in the market.
• The key players are 23andMe, Colour Genomics, Counsyl, Gene by Gene, Laboratory Corporation of America, My Med Lab, Map my genome India, Positive Bioscience, Quest Diagnostics, Request A Test, Sonora Quest Laboratories LLC, Xcode Life Sciences.
• The key strategy of these companies includes R&D investment leading to increased FDA approvals of testing systems and kits.

Segmentation: